With growing competition in emerging markets, Abbott wants to make sure its products stay in the forefront. So, it's rolling out a new branding campaign to cozy up with consumers and amp up its international name recognition.
Antitrust regulators in India have approved the $4 billion sale of Ranbaxy Laboratories to Sun Pharmaceutical on the condition the two companies divest 7 products to avoid market concentration, Bloomberg reports.
Here's another black mark against the pharma industry in India. European regulators are barring a slate of generic drugs whose approvals relied on data generated by India's GVK Biosciences. The treatments weren't named, but they include products sold by a variety of drugmakers, including U.S.-based Mylan and Abbott Laboratories.
Some European Union states have suspended the approvals of drugs tied to a data falsification scandal at CRO GVK Biosciences, and the European Medicines Agency is investigating whether to recommend a continental halt.
India should take a cue from the biotech hotbeds of the U.S. and U.K., a local trade groups says, investing in infrastructure to help foster startups and grow innovation clusters of its own.
A powdered measles vaccine could mean a cheaper option for the developing world that eliminates storage, contamination and waste challenges. And researchers now have one that looks safe in Phase I.
Selling off OTC businesses is the trend du jour in Big Pharma, but Merck KGaA is not jumping on the bandwagon. The company is planning to hold on to its consumer healthcare unit in a move that could deliver a much-needed boost to its slumping drug portfolio.
Some good news for emerging-market ambitions: China is backpedaling on price caps. After shortages prompted the government to ease up on certain price controls earlier this year, officials are now preparing to lift the price controls as early as Jan. 1.
Actavis has a lot to do as it works to bring new acquisition Allergan into the fold. And finding ways to grow the California company's products in China is high on the list.
The FDA is extending its tentacles deeper into China, which exported medical devices worth $3.5 billion to the U.S. in 2012, according to the U.S. Department of Commerce.